Jo Van Ginderachter
Vrije Universiteit Brussel
H-index: 57
Europe-Belgium
Top articles of Jo Van Ginderachter
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Murine cross-reactive human ccr8 binders | 2024/2/15 | ||
An ltbr agonist in combination therapy against cancer | 2024/1/18 | ||
Specific Imaging of CD8+ T-Cell Dynamics with a Nanobody Radiotracer against Human CD8β | Timo WM De Groof Yoline Lauwers Tessa De Pauw Mohit Saxena Cécile Vincke | 2024/4/29 | |
Human ccr8 binders | 2024/3/7 | ||
Human PD-L1-binding immunoglobulins | 2024/1/2 | ||
Q586B2 is a crucial virulence factor during the early stages of Trypanosoma brucei infection that is conserved amongst trypanosomatids | Nature Communications | Benoit Stijlemans Patrick De Baetselier Inge Van Molle Laurence Lecordier Erika Hendrickx | 2024/2/27 |
Non-blocking human ccr8 binders | 2024/2/15 | ||
Hallmarks of cancer affected by the MIF cytokine family | Romina Mora Barthelmess Benoit Stijlemans Jo A Van Ginderachter | 2023/1/6 | |
A few good reasons to use nanobodies for cancer treatment | Neema Ahishakiye Jumapili Maida Zivalj Romina Mora Barthelmess Geert Raes Timo WM De Groof | 2023/9 | |
Self‐Immolative Nanobody‐Cysteine Residue Modification for Controlled Immunodrug Delivery | Advanced Therapeutics | Maximilian Scherger Yannick A Pilger Judith Stickdorn Patric Komforth Sascha Schmitt | 2023/11 |
Development of TAM-Targeted Therapies with Novel Nanobodies Against CD163 | Liudmyla Maksymova Jolien Van Craenenbroeck Yoline Lauwers Ayda Haji Assadi Geert Raes | 2023 | |
Ontogeny, functions and reprogramming of Kupffer cells upon infectious disease | Mohamed Amer Musrati Patrick De Baetselier Kiavash Movahedi Jo A Van Ginderachter | 2023/8/25 | |
Lipocalin-2: A Nurturer of Tumor Progression and a Novel Candidate for Targeted Cancer Therapy | Maida Živalj Jo A Van Ginderachter Benoit Stijlemans | 2023/10/26 | |
Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models | Frontiers in Immunology | Emile J Clappaert Daliya Kancheva Jan Brughmans Ayla Debraekeleer Pauline MR Bardet | 2023/8/9 |
Targeting Lcn-2 as a novel strategy to disrupt the iron-trafficking mechanism within the tumor microenvironment | Mayuk Saibal Gupta Maida Zivalj Benoit Stijlemans Jo Van Ginderachter | 2023 | |
The use of a CD163-specific nanobody-based immunotracer as a clinical imaging agent to study immunosuppressive tumor-associated macrophages | Yoline Lauwers Nick Devoogdt Timo De Groof Cecile Vincke Geert Raes | 2023/10/5 | |
Development of a new immunotracer targeting human CD8+ cytotoxic T cells through recognition of the CD8β chain | Timo De Groof Yoline Lauwers Tessa De Pauw Cecile Vincke Jolien Van Craenenbroeck | 2023 | |
Current status and future expectations of nanobodies in oncology trials | Tessa De Pauw Lynn De Mey Jens M Debacker Geert Raes Jo A Van Ginderachter | 2023/8/3 | |
Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α | Journal of Nuclear Medicine | Yana Dekempeneer Sam Massa Francis Santens Laurent Navarro Marion Berdal | 2023/12/1 |
Blocking the MIF cytokine family to improve cancer therapy | Romina Mora Barthelmess Cecile Vincke Benoit Stijlemans Jo Van Ginderachter | 2023/9/19 |
